Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 19/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791246 | 0.86 | SOS1 (0.32) | SOS1 | |
| SCHEMBL23356052 | 0.86 | SOS1 (0.32) | SOS1 | |
| SCHEMBL30791249 | 0.84 | NPC1 (0.33) | — | |
| SCHEMBL23356079 | 0.84 | NPC1 (0.33) | — | |
| SCHEMBL30791299 | 0.82 | — | — | |
| SCHEMBL30791279 | 0.82 | CCNE2 (0.30) | — | |
| SCHEMBL23356030 | 0.82 | CCNE2 (0.30) | — | |
| SCHEMBL23356077 | 0.82 | — | — | |
| SCHEMBL23356028 | 0.81 | EGFR (0.46) | — | |
| SCHEMBL30791200 | 0.81 | EGFR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| CN-112313232-B | Novel heterocyclic derivatives | JW中外制药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
| EP-3822270-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW Pharmaceutical Corporation (KR) | 2021-05-19 | — | — | EP | disclosed |
| CN-112313232-A | Novel heterocyclic derivatives | JW中外制药公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | NLRP3 365/4885SOS1 2958/4885 |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | NLRP3 806/4885SOS1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.